Stockreport

Eupraxia Pharmaceuticals Reports Six-Month Symptom Data from the Highest Dose Cohort in its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis [Yahoo! Finance]

Eupraxia Pharmaceuticals Inc.  (EPRX) 
PDF The data is important because it is from one of the two doses that are being studied in the placebo-controlled Phase 2b portion of the study. Patients in the highest d [Read more]